Check out our new interview series, The Feeder. We’re speaking with people impacted by kidney disease, and a wide range of experts who are driving change, innovation and hope in the kidney space.
Videos & Features
We’re committed to driving important discussions around kidney disease
Replay of Goldfinch Bio Virtual Event
The Unmet Need in FSGS and GFB-887 as a Novel Precision Medicine Candidate
Originally hosted on Tuesday, March 29, 2022 at 4:00 p.m. ET
Speakers
Anthony Johnson, M.D.
President and Chief Executive Officer, Goldfinch Bio
Katherine Tuttle, M.D.
Exec. Director for Research, Providence Health Care
Professor of Medicine, Univ. of Washington
Investigator, GFB-887 Phase 2 Trial
Our
Proteinuria in FSGS
Fact Stack
We’re excited to launch our Proteinuria in FSGS Fact Stack! This is designed to be a ‘bite-sized’ education campaign to help explain the role that proteinuria plays in Focal Segmental Glomerulosclerosis (FSGS) and its use as a clinically meaningful endpoint to assess investigational kidney disease therapeutics, like GFB-887, our lead precision medicine candidate. Click through each fact!
The Feeder - A Goldfinch Bio Interview Series
The Feeder
June 2021: Hon. William "Mo" Cowan speaks with CEO Tony Johnson
GFB Board member, "Mo" Cowan speaks with CEO Tony Johnson about the evolving biotech landscape.
The Feeder
April 2021: Josh Tarnoff speaks with CEO Tony Johnson
Tony Johnson, MD, speaks with Josh Tarnoff, CEO of NephCure, about the promise of targeted therapies for kidney disease.
The Feeder
March 2021: Kirk Campbell, MD speaks with Liron Walsh, MD
Liron Walsh, MD speaks with Kirk Campbell, MD about his work and the evolving innovation landscape in nephrology.
The Feeder
February 2021: Jill H Speaks with CEO Tony Johnson
Tony Johnson, MD, speaks with Jill, a member of our FSGS Patient Advisory Board, about managing life with FSGS.
Kidney Month 2021 Patient Panel
In commemoration of National Kidney Month, our Patient Advisory Board members graciously joined us for a virtual panel discussion to discuss their experience living with FSGS. We present the discussion in three parts below. We invite you to listen and learn from these inspiring individuals and their powerful stories.
2021 Kidney Month Panel
Part 1 of 3: Introductions and Personal Stories of Living with FSGS
Dine, Jill, Shannon and Kent share their personal, journeys from diagnosis with FSGS to today.
2021 Kidney Month Panel
Part 2 of 3: Current Treatment Options and Unmet Need in FSGS
Our Board members describe their experiences with treatment options currently available to those diagnosed with FSGS.
2021 Kidney Month Panel
Part 3 of 3: Hope for the Future
Our Board members share their hopes for the future and explain why the time is now to shine a spotlight on kidney diseases.
Goldfinch Bio and NephCure Explore Key Topics
Our President and CEO Tony Johnson, MD, recently explored a range of key topics with Josh Tarnoff, President and CEO of NephCure Kidney International, including the promise of targeted therapies for people with kidney diseases, strategies for driving clinical trial participation, engaging the patient perspective, and tackling racial disparities in kidney disease.
GFB:Nephcure
Part 1: Kidney Disease Treatments: Historical Perspectives and Recent Progress
Tony and Josh discuss the recent progress that has been made in developing innovative medicines for kidney disease.
GFB:Nephcure
Part 2: Understanding the Heterogeneity of Nephrotic Syndrome and its Underlying Causes
Tony and Josh discuss the future of precision medicines to target subsets of patients most likely to respond.
GFB:Nephcure
Part 3: Connecting the Patient Community with Clinical Trials
Tony and Josh discuss the patient community's response to an increase in focus on kidney disease drug development.
GFB:Nephcure
Part 4: African Americans and Kidney Disease
Tony and Josh discuss initiatives aimed at overcoming health and clinical trial participation disparities.
Featured Videos
GFB Introduction: NephCure Patient Summit 2021
Tony Johnson and Amanda Grandinetti discuss why GFB is committed to Saving Kidneys and Ending Dialysis.